HealthINTerpath-001 Results Show 42% Lower Risk of Melanoma Recurrence or DeathBy Naomi CalderOct 24, 2026, 7:06 PM UTC
InvestingModerna Shares Fall 17.57% After Melanoma Trial Results Surface EarlyBy Celia RowanOct 23, 2026, 8:19 PM UTC
BusinessPROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORSBy Nasdaq OMXApr 24, 2018, 11:00 AM UTC
BusinessSECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGYBy Nasdaq OMXApr 19, 2018, 10:00 AM UTC
BusinessCombination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical TrialBy Nasdaq OMXNov 13, 2017, 1:31 PM UTC
BusinessPROVECTUS BIOPHARMACEUTICALS RECEIVES SECOND CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICEBy Nasdaq OMXNov 7, 2017, 9:00 PM UTC
BusinessBiothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC
BusinessBiothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC
